Should we screen for prostate cancer? A re-examination of the evidence

Del Mar, Chris B; Glasziou, Paul P; Hirst, Geoffrey H; Wright, Robert G; Hoffmann, Tammy C

doi:10.5694/mja12.11576

Topics

The potential harms from diagnosis, overdiagnosis and treatment must not be overlooked

Despite the results of two large, but conflicting, trials published side by side in 2009, whether prostate cancer screening is beneficial or harmful (or indeterminate) remains unresolved.1,2 Those on either side of the debate read the same information but interpret it differently, declaring that it supports their unchanged positions.

1 Bond University, Gold Coast, QLD.
2 Royal Australian College of General Practitioners Red Book Committee, Melbourne, VIC.
3 Department of Urology and Continence, Mater Health Services, Brisbane, QLD.

Correspondence: cdelmar@bond.edu.au

Acknowledgements:

Tammy Hoffmann is supported by a National Health and Medical Research Council (NHMRC) and Primary Health Care Research, Evaluation and Development Career Development Fellowship (1033038) with funding provided by the Department of Health and Ageing. Paul Glasziou is supported by a NHMRC Australia Fellowship (527500). The funders had no role in the preparation, review and approval of the manuscript.

Competing interests:

No relevant disclosures.

1. Andriole GL, Crawford ED, Grubb RL 3rd, et al; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-1319.
2. Schröder FH, Hugosson J, Roobol MJ, et al; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-1328.
3. Begg S, Vos T, Barker B, et al. The burden of disease and injury in Australia 2003. Canberra: AIHW, 2007. (AIHW Cat. No. PHE 82.) www.aihw.gov.au/publication-detail/?id=6442467990&libID=6442467988 (accessed Mar 2013).
4. Bruner DW, Moore D, Parlanti A, et al. Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer 2003; 107: 797-803.
5. Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. Cancer 2004; 101 (10 Suppl): 2371-2490.
6. Howard DH. Declines in prostate cancer incidence after changes in screening recommendations. Arch Intern Med 2012; 172: 1267-1268.
7. Moyer VA; US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157: 120-134.
8. Baade PD, Youlden DR, Coory MD, et al. Urban-rural differences in prostate cancer outcomes in Australia: what has changed? Med J Aust 2011; 194: 293-296. <MJA full text>
9. Stamey TA, Caldwell M, McNeal JE, et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004; 172: 1297-1301.
10. Jacobsen SJ, Katusic SK, Bergstralh EJ, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA 1995; 274: 1445-1449.
11. Malm J, Lilja H. Biochemistry of prostate specific antigen, PSA. Scand J Clin Lab Invest Suppl 1995; 221: 15-22.
12. Hameed O, Humphrey PA. Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol 2005; 22: 88-104.
13. Berges R, Oelke M. Age-stratified normal values for prostate volume, PSA, maximum urinary flow rate, IPSS, and other LUTS/BPH indicators in the German male community-dwelling population aged 50 years or older. World J Urol 2011; 29: 171-178.
14. Weckermann D, Maassen C, Wawroschek F, Harzmann R. Improved discrimination of prostate cancer and benign prostatic hyperplasia by means of the quotient of free and total PSA. Int Urol Nephrol 1999; 31: 351-359.
15. Coley CM, Barry MJ, Fleming C, Mulley AG. Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians. Ann Intern Med 1997; 126: 394-406.
16. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725-732.
17. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev 2013; (1): CD004720. doi: 10.1002/14651858.CD004720.pub3.
18. Djulbegovic M, Beyth RJ, Neuberger MM, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010; 341: c4543.
19. Kjellman A, Akre O, Norming U, et al. 15-year followup of a population based prostate cancer screening study. J Urol 2009; 181: 1615-1621; discussion 1621.
20. Labrie F, Candas B, Cusan L, et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 2004; 59: 311-318.
21. Sandblom G, Varenhorst E, Löfman O, et al. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol 2004; 46: 717-723; discussion 724.
22. Glasziou PP. Meta-analysis adjusting for compliance: the example of screening for breast cancer. J Clin Epidemiol 1992; 45: 1251-1256.
23. Alemozaffar M, Regan MM, Cooperberg MR, et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011; 306: 1205-1214.
24. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358: 1250-1261.
25. Fall K, Fang F, Mucci LA, et al. Immediate risk for cardiovascular events and suicide following a prostate cancer diagnosis: prospective cohort study. PLoS Med 2009; 6: e1000197.
26. Bowden FJ, Roberts J, Collignon PJ. Prostate cancer screening and bacteraemia [letter]. Med J Aust 2008; 188: 60. <MJA full text>
27. Smith DP, King MT, Egger S, et al. Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. BMJ 2009; 339: b4817.
28. Heijnsdijk EAM, Wever EM, Auvinen A, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012; 367: 595-605.
29. Epstein MM, Edgren G, Rider JR, et al. Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst 2012; 104: 1335-1342.
30. Sakr WA, Grignon DJ, Haas GP, et al. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 1996; 30: 138-144.
31. Dunn IB, Kirk D. Legal pitfalls in the diagnosis of prostate cancer. BJU Int 2000; 86: 304-307.
32. Guerra CE, Jacobs SE, Holmes JH, Shea JA. Are physicians discussing prostate cancer screening with their patients and why or why not? A pilot study. J Gen Intern Med 2007; 22: 901-907.
33. Hoffman RM, Helitzer DL. Moving towards shared decision making in prostate cancer screening. J Gen Intern Med 2007; 22: 1056-1057.
34. Volk RJ, Hawley ST, Kneuper S, et al. Trials of decision aids for prostate cancer screening: a systematic review. Am J Prev Med 2007; 33: 428-434.
35. Evans R, Joseph-Williams N, Edwards A, et al. Supporting informed decision making for prostate specific antigen (PSA) testing on the web: an online randomized controlled trial. J Med Internet Res 2010; 12: e27.
36. Dorfman CS, Williams RM, Kassan EC, et al. The development of a web- and a print-based decision aid for prostate cancer screening. BMC Med Inform Decis Mak 2010; 10: 12.
37. Joseph-Williams N, Evans R, Edwards A, et al. Supporting informed decision making online in 20 minutes: an observational web-log study of a PSA test decision aid. J Med Internet Res 2010; 12: e15.

Online responses are no longer available. Please refer to our instructions for authors page for more information.